Loading patent…
AssigneeResearch Development Foundation
InventorsBob G. Sanders, Kimberly Kline, Weiping Yu, Hui Liu, Feras Hantash
Estimating the term…
The present invention provides a novel tocopherol associated protein (TAP-38) DNA/protein with a 76 nucleotide base deletion resulting in a 25 amino acid deletion, followed by 90 novel nucleotides that code for 30 novel amino acids that are not expressed by TAP-46. The present invention provides data showing that TAP-38 enhances the apoptotic inducing properties of tocopherol based compounds, and blockage of TAP reduces the effectiveness of tocopherol based compounds. Thus, the present invention claim that expression of TAP-38 by tumor cells enhances the apoptotic inducing properties of tocopherol based compounds. The present invention provides aerosol liposome/transfection/infection methods for delivery of TAP-38 and TAP-46 cDNA plasmids separately and in combination with tocopherol based apoptotic inducing agents as well as with other chemotherapeutic agents as a method for treatment and prevention of cellular proliferative diseases and disorders.
Isolated and purified DNA encoding tocopherol associated protein-p38 selected from the group consisting of:
Isolated and purified tocopherol associated protein-p38 coded for by DNA selected from the group consisting of:
A mutated tocopherol associated protein-p38, wherein said protein has a mutation that enhances biological function, said mutation selected from the group consisting of a mutation to the ligand binding domain, a mutation to the transactivation domain, a mutation to the nuclear localization domain, a mutation to the sequence specific DNA binding domain, a mutation to the non-sequence specific DNA binding domain, a mutation to the dimerization or tetramerization domain, and a mutation to a phosphorylation and dephosphrylation site.
A method for the treatment of cell proliferative diseases comprising the step of:
Dependencies are inferred from the claim text.